← Back to Search

Not Applicable

LY3549492 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through final follow-up at approximately day 76
Awards & highlights

Summary

This study is evaluating whether a drug may be safe for human consumption.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through final follow-up at approximately day 76
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through final follow-up at approximately day 76 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
PK: Maximum Concentration (Cmax) of LY3549492
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3549492

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3549492 (Part B)Experimental Treatment1 Intervention
LY3549492 administered orally as multiple ascending doses.
Group II: LY3549492 (Part A)Experimental Treatment1 Intervention
LY3549492 administered orally as single ascending doses.
Group III: PlaceboPlacebo Group1 Intervention
Placebo administered orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3549492
2021
Completed Phase 1
~160

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,629 Previous Clinical Trials
3,218,056 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,351 Previous Clinical Trials
416,422 Total Patients Enrolled
~12 spots leftby Jul 2025